The nation of Zimbabwe has declined a significant American health deal worth 367 million US dollars (272 million pounds) spanning five years over Washington's insistence on confidential biological samples.
The decision came to light after a government memo from December was disclosed, indicating that Head of State Emmerson Mnangagwa felt the arrangement was "lopsided".
An official representative later clarified that the US was requesting biological samples for research and commercial gain while refused to guarantee the resulting advantages from any future treatments.
"We will now turn to the difficult and regrettable process of ending our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy noted the United States had donated more than $1.9bn as health assistance to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has called for further negotiations to find a deal suitable to all parties so the country's critical HIV treatment initiative can proceed.
Wider Implications
This rejection comes after a comparable case in neighbouring Kenya, where a high court suspended a related health funding agreement following legal challenges were filed about the safety of Kenyans' medical information.
Since resuming the presidency last year, US President Donald Trump has reduced foreign aid and closed the US Agency for International Development (USAID).
USAID had overseen assistance for the American government, but Trump stated its spending was "wasteful" and his government was seeking direct bilateral deals to boost openness and accountability.
As per reports, 16 African countries have so far agreed to these new health pacts, representing more than $18.3bn in new funding.
Specifics of the Declined Agreement
The funds for Zimbabwe would have gone towards "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this cooperation would have delivered significant benefits for the people of Zimbabwe, particularly the 1.2 million men, women and children currently receiving HIV treatment through American-funded initiatives," Tremont commented.
However, official spokesman Nick Mangwana argued the arrangement was "unequal".
"Zimbabwe was being asked to share its genetic material and health information indefinitely, with no corresponding promise of access to any scientific breakthroughs – like new medicines or tests – that might be developed from that provided information," Mangwana explained.
"Put simply, our nation would provide the basic resources for scientific discovery with no certainty that the end products would be accessible to our people if a new pandemic emerge."
National Interest and International Frameworks
He also pointed out that the American exit from the World Health Organization (WHO) and its push of bilateral deals were disrupting frameworks previously set up via the international organization.
The spokesperson cited its Pathogen Access and Benefit Sharing framework designed to deal with future global health emergencies.
"This mechanism is intended to ensure that when a nation contributes its samples, the resulting advantages – including medicines and cures – are distributed fairly, not commercialised solely by those with the capability to create them."
The government's concerns regarding the US deal "are not meant as opposition to America," Mangwana stressed.
"We encourage further discussions with our US partners on how future collaboration might be designed in a manner that respects the independence and dignity of each country."
Medical Community Response
A leading public health body said it understood the government's concerns, but recommended that talks should continue considering much of the country's HIV programmes were funded by international support.
"Where specific concerns arise, including those relating to information security or implementation frameworks, these can frequently be resolved through detailed discussion and mutually agreed protections," it commented.
The halted deal underscores the ongoing debate between accepting crucial foreign assistance and safeguarding national sovereignty in an increasingly data-driven world.